Cargando...
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Aβ) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bap...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Academy of Neurology
2009
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2790221/ https://ncbi.nlm.nih.gov/pubmed/19923550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181c67808 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|